Table 6 Cox regression analyses assessing unadjusted, age & sex-adjusted and multivariable-adjusted risk of Covid19-related mortality in the total study cohort (N = 79,083)

 Age (continuous yrs)

1.13 (1.12–1.15) < 0.001

1.14 (1.12–1.16) < 0.001

1.08 (1.06–1.10) < 0.001

 Sex, women

0.88 (0.62–1.25) 0.472

0.60 (0.42–0.85) 0.004

0.55 (0.37–0.81) 0.003

 Nursing-home residence

57.04 (40.11–81.11) < 0.001

17.05 (11.28–25.78) < 0.001

12.56 (8.07–19.54) < 0.001

 Neurological disease

10.30 (6.79–15.61) < 0.001

2.74 (1.77–4.23) < 0.001

1.35 (0.86–2.14) 0.198

 Renal disease

3.83 (2.44–6.03) < 0.001

0.99 (0.62–1.57) 0.952

0.98 (0.60–1.60) 0.943

 Cancer

2.51 (1.59–3.94) < 0.001

1.43 (0.90–2.25) 0.130

1.39 (0.86–2.23) 0.178

 Rheumatic disease

0.05 (0.01–92.92) 0.433

NA (−) -

NA (−) -

 Respiratory disease

2.77 (1.81–4.24) < 0.001

1.66 (1.08–2.55) 0.021

1.17 (0.66–2.08) 0.603

 Cardiac disease

3.79 (2.66–5.41) < 0.001

1.47 (1.02–2.11) 0.039

1.23 (0.81–1.85) 0.333

 Atrial fibrillation

4.58 (2.91–7.20) < 0.001

1.30 (0.82–2.07) 0.266

1.08 (0.54–2.16) 0.824

 Liver disease

1.32 (0.42–4.15) 0.635

1.71 (0.54–5.37) 0.361

1.17 (0.37–3.77) 0.790

 Diabetes

2.45 (1.68–3.56) < 0.001

1.50 (1.03–2.19) 0.033

0.85 (0.41–1.77) 0.670

 Hypertension

2.22 (1.54–3.21) < 0.001

0.74 (0.51–1.07) 0.110

0.79 (0.50–1.24) 0.297

 Obesity

0.84 (0.56–1.27) 0.420

0.84 (0.56–1.28) 0.418

0.89 (0.57–1.36) 0.580

 Smoking

0.51 (0.27–0.94) 0.031

1.66 (0.87–3.18) 0.126

1.20 (0.61–2.34) 0.600

 Alcoholism

1.07 (0.34–3.36) 0.911

1.92 (0.60–6.13) 0.272

1.07 (0.33–3.54) 0.910

 Diuretics

5.49 (3.83–7.87) < 0.001

1.88 (1.29–2.74) 0.001

1.48 (0.97–2.25) 0.068

 Beta blockers

2.22 (1.47–3.37) < 0.001

1.30 (0.86–1.97) 0.214

1.24 (0.78–1.98) 0.355

 ACEIs

1.33 (0.89–1.99) 0.167

0.77 (0.51–1.15) 0.194

0.77 (0.49–1.22) 0.265

 ARBs

0.77 (0.42–1.43) 0.408

0.46 (0.25–0.85) 0.013

0.52 (0.26–1.01) 0.054

 Calcium channel blockers

1.90 (1.15–3.13) 0.012

0.99 (0.60–1.63) 0.970

1.14 (0.67–1.94) 0.633

 Statins

1.04 (0.67–1.59) 0.877

0.73 (0.47–1.12) 0.147

0.91 (0.54–1.52) 0.709

 Oral anticoagulants

3.08 (1.84–5.13) < 0.001

1.05 (0.63–1.76) 0.854

0.87 (0.40–1.92) 0.734

 Antiplatelet drugs

3.02 (2.04–4.46) < 0.001

1.21 (0.81–1.80) 0.356

1.08 (0.67–1.74) 0.750

 Insulin

2.69 (1.49–4.89) 0.001

1.72 (0.95–3.13) 0.073

1.01 (0.51–2.02) 0.970

 Oral antidiabetic drugs

2.35 (1.58–3.50) < 0.001

1.61 (1.08–2.40) 0.019

2.14 (1.03–4.43) 0.042

 Inhaled respiratory drugs

3.40 (2.23–5.18) < 0.001

1.81 (1.19–2.78) 0.006

1.45 (0.82–2.58) 0.207

 Antineoplastic agents

1.60 (0.59–4.33) 0.355

1.65 (0.61–4.47) 0.325

1.55 (0.55–4.39) 0.412

 Systemic corticosteroids

3.19 (1.41–7.25) 0.006

1.84 (0.81–4.19) 0.144

1.88 (0.80–4.41) 0.145

 NSADs

0.05 (0.01–1.42) 0.078

NA (−) -

NA (−) -

 Antihistamines

0.05 (0.01–2.38) 0.126

NA (−) -

NA (−) -

 Proton-Pump Inhibitors

2.82 (1.98–4.12) < 0.001

1.18 (0.83–1.69) 0.361

0.93 (0.61–1.41) 0.716

 Benzodiazepines

2.16 (1.47–3.17) < 0.001

1.48 (1.00–2.19) 0.052

1.40 (0.93–2.08) 0.104

 Flu vaccine in prior autumn

6.14 (4.16–9.04) < 0.001

1.82 (1.21–2.73) 0.004

1.55 (0.98–2.47) 0.063

 PPV23

4.59 (3.13–6.72) < 0.001

0.86 (0.58–1.29) 0.468

1.00 (0.59–1.67) 0.990

 PCV13

2.30 (0.85–6.23) 0.101

1.37 (0.51–3.71) 0.537

1.15 (0.41–3.21) 0.794

 Tetanus

1.09 (0.75–1.58) 0.659

0.62 (0.43–0.90) 0.013

0.68 (0.43–1.08) 0.103